Exercise therapy and cardiovascular toxicity in cancer
Cardio-oncology is an emerging discipline focused predominantly on the detection and
management of cancer treatment–induced cardiac dysfunction (cardiotoxicity), which …
management of cancer treatment–induced cardiac dysfunction (cardiotoxicity), which …
Cancer treatment as an accelerated aging process: assessment, biomarkers, and interventions
A Hurria, L Jones, HB Muss - American Society of Clinical Oncology …, 2016 - ascopubs.org
An accumulating body of evidence supports the hypothesis that cancer and/or cancer
treatment is associated with accelerated aging. The majority of these data come from the …
treatment is associated with accelerated aging. The majority of these data come from the …
Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial
A Tashakori Beheshti, H Mostafavi Toroghi, G Hosseini… - Cardiology, 2016 - karger.com
Objective: The aim of this study is to evaluate the preventive effects of carvedilol on
doxorubicin-induced cardiotoxicity. Methods: In this trial, 70 female patients with breast …
doxorubicin-induced cardiotoxicity. Methods: In this trial, 70 female patients with breast …
Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non‐small cell lung cancer: results of a prospective cardiovascular …
MS Anker, N Ebner, B Hildebrandt… - European journal of …, 2016 - Wiley Online Library
Aims Patients with advanced cancer have been shown to suffer from abnormal cardiac
function and impaired exercise capacity that may contribute to their impaired quality of life …
function and impaired exercise capacity that may contribute to their impaired quality of life …
Long-term cardiopulmonary consequences of treatment-induced cardiotoxicity in survivors of ERBB2-positive breast cancer
Importance Trastuzumab improves outcomes in patients withERBB2-positive
(formerlyHER2) breast cancer but is associated with treatment-induced cardiotoxicity, most …
(formerlyHER2) breast cancer but is associated with treatment-induced cardiotoxicity, most …
Persistent impairment in cardiopulmonary fitness after breast cancer chemotherapy
PURPOSE: Anthracycline chemotherapy (AC) is associated with acute reductions in
cardiopulmonary fitness (VO2peak). We sought to determine whether changes in VO2peak …
cardiopulmonary fitness (VO2peak). We sought to determine whether changes in VO2peak …
Cardio-oncology: what you need to know now for clinical practice and echocardiography
CM Larsen, SL Mulvagh - Echo Research & Practice, 2017 - Springer
Cardio-oncology is a rapidly growing field aimed at minimizing the effects of cardiovascular
morbidity and mortality in cancer survivors. To meet this aim, patients are assessed at …
morbidity and mortality in cancer survivors. To meet this aim, patients are assessed at …
Cancer history portends worse acute and long-term noncardiac (but not cardiac) mortality after primary percutaneous coronary intervention for acute ST-segment …
F Wang, R Gulati, RJ Lennon, BR Lewis, J Park… - Mayo Clinic …, 2016 - Elsevier
Objective To define the effect of a history of cancer on in-hospital and long-term mortality
after primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial …
after primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial …
Traditional markers of cardiac toxicity fail to detect marked reductions in cardiorespiratory fitness among cancer patients undergoing anti-cancer treatment
Aims Left ventricular ejection fraction (LVEF) is standard of care for evaluating
chemotherapy-associated cardiotoxicity, although global longitudinal strain (GLS) offers …
chemotherapy-associated cardiotoxicity, although global longitudinal strain (GLS) offers …
Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group
V Narayan, M Harrison, H Cheng, S Kenfield… - … Oncology: Seminars and …, 2020 - Elsevier
Survivorship care for patients with prostate cancer requires careful consideration of unique
disease-specific factors, including the prolonged natural disease history, the potential for …
disease-specific factors, including the prolonged natural disease history, the potential for …